|
|
Blood, 1 February 2005, Vol. 105, No. 3, pp. 1102-1105.
Prepublished online as a Blood First Edition Paper on October 5, 2004; DOI 10.1182/blood-2004-08-3253.
 Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis
Ton Lisman,
Philip G. de Groot,
Joost C.M. Meijers, and
Frits R. Rosendaal
From the Thrombosis and Haemostasis Laboratory, Department of Haematology, University Medical Centre, Utrecht, The Netherlands; Institute of Biomembranes, Utrecht University, Utrecht, The Netherlands; Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; and Department of Clinical Epidemiology and Haemostasis and Thrombosis Research Center, Leiden University Medical Center, Leiden, The Netherlands.
The role of the fibrinolytic system in the development of deep vein thrombosis (DVT) is unclear. We determined the plasma fibrinolytic potential of patients enrolled in the Leiden Thrombophilia Study (LETS), a population-based case-control study on risk factors for DVT. Plasma fibrinolytic potential was determined in 421 patients and 469 control subjects by means of a tissue factor–induced and tissue-type plasminogen activator (tPA)–induced clot lysis assay. Using clot lysis times above the 70th, 80th, 90th, 95th, and 99th percentiles of the values found in control subjects as cut-off levels, we found a dose-dependent increase in risk for DVT in patients with hypofibrinolysis (odds ratios of 1.4, 1.6, 1.9, 2.1, and 2.2, respectively). This indicates a 2-fold increased risk of DVT in subjects with clot lysis times above the 90th percentile. The risk increase was not affected by age or sex (adjusted odds ratio for 90th percentile, 2.0), and after correction for all possible confounders (age, sex, and levels of procoagulant proteins shown to associate with clot lysis times in the control population), the risk estimate was marginally reduced (odds ratio, 1.6 for 90th percentile). Taken together, these results indicate that plasma hypofibrinolysis constitutes a risk factor for venous thrombosis, with a doubling of the risk at clot lysis times that are present in 10% of the population.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. A. Campbell, K. A. Overmyer, C. H. Selzman, B. C. Sheridan, and A. S. Wolberg
Contributions of extravascular and intravascular cells to fibrin network formation, structure, and stability
Blood,
November 26, 2009;
114(23):
4886 - 4896.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Undas, K. Zawilska, M. Ciesla-Dul, A. Lehmann-Kopydlowska, A. Skubiszak, K. Ciepluch, and W. Tracz
Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives
Blood,
November 5, 2009;
114(19):
4272 - 4278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Romay-Penabad, M. G. Montiel-Manzano, T. Shilagard, E. Papalardo, G. Vargas, A. B. Deora, M. Wang, A. T. Jacovina, E. Garcia-Latorre, E. Reyes-Maldonado, et al.
Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo
Blood,
October 1, 2009;
114(14):
3074 - 3083.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. M.K. Williams, A. M. Carter, B. Kato, M. Falchi, L. Bathum, G. Surdulescu, K. O. Kyvik, A. Palotie, T. D. Spector, P. J. Grant, et al.
Identification of Quantitative Trait Loci for Fibrin Clot Phenotypes: The EuroCLOT Study
Arterioscler Thromb Vasc Biol,
April 1, 2009;
29(4):
600 - 605.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.J. van Stralen, C.J.M. Doggen, I.D. Bezemer, E.R. Pomp, T. Lisman, and F.R. Rosendaal
Mechanisms of the Factor V Leiden Paradox
Arterioscler Thromb Vasc Biol,
October 1, 2008;
28(10):
1872 - 1877.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Carter, C. M. Cymbalista, T. D. Spector, P. J. Grant, and on behalf of the EuroCLOT Investigators
Heritability of Clot Formation, Morphology, and Lysis: The EuroCLOT Study
Arterioscler Thromb Vasc Biol,
December 1, 2007;
27(12):
2783 - 2789.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Heit
Thrombophilia: Common Questions on Laboratory Assessment and Management
Hematology,
January 1, 2007;
2007(1):
127 - 135.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Cesarman-Maus, N. P. Rios-Luna, A. B. Deora, B. Huang, R. Villa, M. d. C. Cravioto, D. Alarcon-Segovia, J. Sanchez-Guerrero, and K. A. Hajjar
Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome
Blood,
June 1, 2006;
107(11):
4375 - 4382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. K. Hennan, H. Elokdah, M. Leal, A. Ji, G. S. Friedrichs, G. A. Morgan, R. E. Swillo, T. M. Antrilli, A. Hreha, and D. L. Crandall
Evaluation of PAI-039 [{1-Benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic Acid], a Novel Plasminogen Activator Inhibitor-1 Inhibitor, in a Canine Model of Coronary Artery Thrombosis
J. Pharmacol. Exp. Ther.,
August 1, 2005;
314(2):
710 - 716.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Sturm, A. Sandhofer, C. J.M. Doggen, N. L. Smith, R. N. Lemaitre, S. R. Heckbert, F. R. Rosendaal, and B. M. Psaty
Dyslipidemia and Thrombosis: Causal Relationship or Epiphenomenon of Sedentary Lifestyle?
Arterioscler Thromb Vasc Biol,
March 1, 2005;
25(3):
e19 - e19.
[Full Text]
[PDF]
|
|
|
|
|
